The 2026 Cholesterol Guidelines Just Rewrote the Rules of Heart Disease Prevention

On March 13, 2026, the American College of Cardiology and American Heart Association released updated dyslipidemia guidelines. This is the first full overhaul since 2018 and the most consequential shift in lipid management philosophy since the controversial 2013 decision to abandon cholesterol treatment targets altogether. That 2013 call replaced specific LDL-C goals with vague “intensity-based” statin recommendations, and it frustrated cardiologists for over a decade. The new guidelines walk it back. Specific numbers are in. ApoB gets a formal seat at the table. And for the first time, every adult should have their Lp(a) measured at least once.

The document runs to hundreds of pages across JACC and Circulation, backed by eleven co-sponsoring medical societies. What it says, stripped to its core: measure more, treat earlier, treat harder, and stop pretending that a basic lipid panel tells the whole story. The 2026 guidelines concede what preventive cardiologists have been arguing (loudly, and with accumulating data) for years. The old approach left too many people undertreated. LDL-C alone misses a substantial fraction of risk. And waiting for a heart attack to get aggressive with lipid management is indefensible given what we now know about early atherosclerosis. This matters for every Canadian and American adult who thinks their annual physical is covering the basics.

The Return of Treatment Targets

For primary prevention, the guidelines now recommend an LDL-C below 100 mg/dL for individuals at borderline or intermediate risk, and below 70 mg/dL for those at high risk. Secondary prevention patients, meaning people who already have documented atherosclerotic cardiovascular disease, face an even more aggressive target: below 55 mg/dL if they’re classified as very high risk. These are real numbers, printed in a guideline document, with specific therapeutic escalation steps if patients don’t hit them. The era of “just put them on moderate-intensity rosuvastatin and hope for the best” is officially over. The guidelines also formally recommend transitioning from the Pooled Cohort Equations to the newer PREVENT (Predicting Risk of Cardiovascular Disease EVENTs) calculator for 10-year risk estimation, a tool validated in the Multi-Ethnic Study of Atherosclerosis and shown to produce more accurate predictions across diverse populations.

Why does this matter beyond academic cardiology? Because the 2013 framework created a clinical vacuum. Without targets, many primary care physicians defaulted to starting a statin and never rechecking. That problem was compounded by the 15-minute appointment structure that dominates Canadian and American family medicine. A 2024 analysis in Circulation found that among patients on statin therapy, roughly 40% weren’t achieving the LDL-C reductions that their risk profiles warranted, and nobody was escalating treatment because there was technically no goal to miss. The targets give clinicians something to measure against, and more critically, they give patients a concrete reason to care about their follow-up bloodwork.

ApoB Finally Gets Its Due

The 2026 guidelines formally state that apolipoprotein B is more strongly associated with cardiovascular events than LDL-C or non-HDL-C. That single sentence has been a long time coming. The data supporting ApoB over LDL-C as a risk predictor has been accumulating for well over a decade, but institutional inertia kept it sidelined in clinical practice. A systematic review published in 2024 found that in nine out of nine discordance studies (situations where ApoB and LDL-C told different stories about the same patient) cardiovascular event risk tracked with ApoB. In seven of those nine, ApoB also beat non-HDL-C. The most recent UK Biobank analysis, published in 2025, confirmed that ApoB outperforms LDL particle number as a cardiovascular risk marker, with risk already elevated at as little as 2% discordance between the measures.

The underlying biology is easy to grasp once you see it. LDL-C measures the cholesterol mass inside LDL particles. ApoB counts the actual particles, since each atherogenic lipoprotein (LDL, VLDL, intermediate-density lipoprotein, Lp(a)) carries exactly one ApoB molecule on its surface. A patient can have a seemingly normal LDL-C of 95 mg/dL yet carry an elevated number of small, dense LDL particles, each one capable of penetrating the arterial endothelium and seeding plaque formation. That patient’s ApoB would flag the risk. Their standard lipid panel would miss it entirely. An estimated 20 to 30 percent of the population shows clinically meaningful discordance between LDL-C and ApoB, and for those individuals, relying solely on the standard panel systematically underestimates their cardiovascular risk.

The new guidelines recommend ApoB testing particularly for patients with elevated triglycerides, diabetes, or seemingly adequate LDL-C levels who may still be carrying excessive atherogenic particle burden. In practice, this means a meaningful percentage of patients who thought they were “controlled” on statins may discover they need therapeutic escalation: adding ezetimibe, a PCSK9 inhibitor like evolocumab or alirocumab, or the newer twice-yearly injectable inclisiran. Real-world registry data published in Lipids in Health and Disease in 2026 showed that PCSK9 inhibitor therapy reduced major adverse cardiovascular events to 2.6 per 100 person-years, with inclisiran’s bi-annual healthcare-administered dosing eliminating the adherence problem that plagues daily oral medications. The convenience factor shouldn’t be dismissed. Adherence to statins drops below 50% within two years of initiation in most studies.

Lp(a): The Risk Factor You Can’t Outrun

The most consequential new recommendation may be universal Lp(a) screening. The guidelines now state that lipoprotein(a) should be measured at least once in every adult to identify individuals at higher ASCVD risk. Lp(a) is almost entirely genetically determined. Diet doesn’t move it, and neither does exercise. Statins can raise it slightly. About 20% of the global population carries elevated Lp(a), and those individuals face a higher lifetime risk of myocardial infarction, ischemic stroke, and aortic valve calcification. Most of them have no idea.

The timing of this screening recommendation coincides with a pipeline of Lp(a)-lowering drugs that would have seemed implausible a decade ago. Pelacarsen, an antisense oligonucleotide that blocks hepatic production of the apo(a) protein, demonstrated greater than 80% Lp(a) reduction in phase 2b trials. Its phase 3 cardiovascular outcomes trial, Lp(a) HORIZON, enrolled patients with established CVD and elevated Lp(a), with results expected later in 2026. Three small-interfering RNA agents (olpasiran, lepodisiran, and zerlasiran) have shown Lp(a) reductions between 80% and nearly 100% in earlier-phase studies, each with its own phase 3 outcomes trial running. If even one of these drugs demonstrates cardiovascular event reduction proportional to its Lp(a) lowering, it will open a therapeutic category that didn’t exist before. We’d have, for the first time, a targeted treatment for a genetic cardiovascular risk factor with no current approved pharmacological intervention.

The clinical value of testing right now, before any of these drugs hit the market, is risk stratification. A patient who discovers their Lp(a) sits at 200 nmol/L doesn’t get the luxury of watching a borderline LDL-C and waiting it out. You treat early, you treat aggressively with the tools available (high-intensity statins, ezetimibe, PCSK9 inhibition) and you manage every other modifiable risk factor with less tolerance for “close enough.” Knowing your Lp(a) doesn’t change what drugs you take today, but it changes how urgently you take them and how aggressively your physician should be managing everything else.

Seeing the Disease Before It Strikes

The guidelines also clarify the expanding role of coronary artery calcium scoring, the low-dose CT scan that directly images calcium deposits in coronary artery walls. A CAC score of zero remains the single most powerful negative predictor in cardiovascular medicine. It means you don’t have meaningful coronary atherosclerosis right now, and your near-term risk is very low regardless of what risk calculators estimate. On the opposite end, a CAC score above 300 carries a risk profile equivalent to someone who has already survived a heart attack, stroke, or peripheral artery disease, even if that person feels perfectly healthy and runs marathons on weekends.

A 2024 paper in JACC: Advances proposed formalizing CAC into a staging system, arguing that the score shouldn’t merely inform whether to start a statin but should sort patients into distinct management tiers with escalating treatment intensity. The American Heart Association followed in 2025 with a scientific statement endorsing opportunistic CAC detection, which means extracting coronary calcium data from chest CTs ordered for entirely unrelated reasons: lung cancer screening, trauma workups, that sort of thing. Approximately 19 million non-cardiac chest CTs are performed annually in the United States alone, representing a massive pool of unscreened individuals whose coronary disease status is literally already captured in imaging data that gets ignored. The MESA dataset continued generating insights in 2025, with analyses showing that CAC scoring delivered its greatest clinical value in patients classified as low or borderline risk by conventional tools. Think about the 45-year-old with a calculated 10-year risk of 5% who, upon scanning, turns out to have a score of 250 and a coronary artery age decades older than their chronological one.

Inflammation: The Other Half of the Equation

A 2025 ACC Scientific Statement on inflammation and cardiovascular disease codified something the CANTOS trial proved back in 2017: that inflammation drives atherosclerotic events independently of cholesterol levels. In CANTOS, inhibiting the interleukin-1β pathway with canakinumab reduced recurrent cardiovascular events by 15 to 17 percent in statin-treated patients, a benefit comparable to what PCSK9 inhibitors achieve, without moving LDL-C at all. The implication was stark but took years to translate into practice, partly because canakinumab carried infection risks and a price tag that made population-level use impractical. What it proved conceptually, though, was that a patient could have their LDL perfectly controlled and still face substantial residual risk driven by arterial inflammation.

Colchicine filled the gap. The COLCOT and LoDoCo2 randomized trials demonstrated that 0.5 mg of daily colchicine, an ancient gout drug that’s cheap and widely available, reduced recurrent cardiovascular events by roughly 25% in patients with chronic stable atherosclerosis. A meta-analysis in the European Heart Journal in 2025 confirmed the benefit across long-term follow-up. The FDA has since approved low-dose colchicine as the first anti-inflammatory agent specifically indicated for cardiovascular event reduction, and the mechanism is relatively straightforward: colchicine suppresses neutrophil activation and dampens the inflammatory signaling that destabilizes vulnerable coronary plaques. For patients whose high-sensitivity C-reactive protein remains above 2 mg/L despite adequate statin therapy (a condition the ACC now labels “residual inflammatory risk”) it represents a targeted intervention addressing a dimension of cardiovascular risk that no lipid-lowering drug touches.

What This Means for Patients

The thread connecting all of these shifts is specificity. The 2026 guidelines push cardiology further from population-level averages and closer to individual risk characterization. ApoB reveals what LDL-C misses. Lp(a) exposes a genetic liability that no lifestyle modification addresses. CAC scanning shows you the disease itself rather than a statistical estimate of it. Inflammatory markers capture a pathological process that lipid panels are blind to. Each layer adds resolution to a risk picture that, for most patients, was previously drawn in crayon.

The practical barrier is access. Most family physicians in Canada and the United States don’t routinely order ApoB, have never checked a patient’s Lp(a), and couldn’t refer for a timely CAC scan even if they wanted to. Provincial health plans don’t reliably reimburse these tests, and wait times in the public system can stretch for months. The 2026 guidelines are aspirational for much of the healthcare infrastructure that’s supposed to implement them. The widening gap between what the evidence supports and what the average patient receives is exactly the problem that concierge and preventive medicine models exist to address. Heart disease remains the leading killer across North America, and the majority of cardiac events happen in people who didn’t know they were at risk. The tools to find those people earlier exist now. The guidelines finally say so. For further insights on how preventive cardiology interacts with genetic testing for sudden cardiac arrhythmias, consider reading about sudden arrhythmic death syndrome.

---

References

1. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Journal of the American College of Cardiology, 2026. DOI: 10.1016/j.jacc.2025.11.016 www.jacc.org/doi/10.1016/j.jacc.2025.11.016

2. Apolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice. Circulation, 2024. DOI: 10.1161/CIRCULATIONAHA.124.068885 www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.068885

3. Role of Apolipoprotein B in the Clinical Management of Cardiovascular Risk in Adults: An Expert Clinical Consensus. National Lipid Association, 2025. PMC11734832 pmc.ncbi.nlm.nih.gov/articles/PMC11734832/

4. Apolipoprotein B Outperforms Low Density Lipoprotein Particle Number as a Marker of Cardiovascular Risk in the UK Biobank. PubMed, 2025. PMID: 40887080 pubmed.ncbi.nlm.nih.gov/40887080/

5. Coronary Artery Calcium Staging to Guide Preventive Interventions: A Proposal and Call to Action. JACC: Advances, 2024. DOI: 10.1016/j.jacadv.2024.101287 www.jacc.org/doi/10.1016/j.jacadv.2024.101287

6. Opportunistic Detection of Coronary Artery Calcium on Noncardiac Chest CT. AHA Scientific Statement. Circulation, 2025. DOI: 10.1161/CIR.0000000000001382 www.ahajournals.org/doi/10.1161/CIR.0000000000001382

7. Utility of Coronary Artery Calcium Scoring in Low-Risk Patients: MESA. Journal of Cardiovascular Computed Tomography, 2025. ScienceDirect www.sciencedirect.com/science/article/pii/S2666667725004040

8. Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement. JACC, 2025. DOI: 10.1016/j.jacc.2025.08.047 www.jacc.org/doi/10.1016/j.jacc.2025.08.047

9. Long-Term Trials of Colchicine for Secondary Prevention of Vascular Events: A Meta-Analysis. European Heart Journal, 2025. Oxford Academic academic.oup.com/eurheartj/article/46/26/2552/8123897

10. Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects. Circulation, 2025. DOI: 10.1161/CIRCULATIONAHA.124.069210 www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.069210

11. Current Clinical Trials for Treating Elevated Lipoprotein(a). PMC, 2025. PMC12282488 pmc.ncbi.nlm.nih.gov/articles/PMC12282488/

12. Real-World Effectiveness and Cardiovascular Outcomes of PCSK9 Inhibitor Therapy: A Prospective Registry Study. Lipids in Health and Disease, 2026. Springer Nature link.springer.com/article/10.1186/s12944-026-02897-3

13. PREVENT Risk Score vs the Pooled Cohort Equations in MESA. JACC: Advances, 2025. DOI: 10.1016/j.jacadv.2025.101825 www.jacc.org/doi/10.1016/j.jacadv.2025.101825

Word count: ~2,100